Patheon Inc., a provider of contract development and commercial manufacturing services to the global pharmaceutical industry, today announced plans for additional investment in its Milton Park facility.
Kemwell Biopharma Pvt. Ltd., a global pharmaceutical contract development and manufacturing company, announced today that its Oral Solids manufacturing facility located in Bangalore, India has successfully completed a U.S. Food and Drug Administration (USFDA) inspection.
A new study shows how important it is for men to carefully consider treatments for early-stage prostate cancer.
Danish pharmaceutical company Novo Nordisk A/S has reported a 23 percent growth in fourth-quarter net profit on strong sales of diabetic drugs and gave a positive outlook as regulators worldwide approved its latest range of insulin products.
Teva Pharmaceutical Industries Ltd. announced today the termination of its collaboration with CureTech Ltd.
Tapemark has announced the addition of several new capabilities for transdermal patches, including the formulation, blending, and coating steps in the patch manufacturing process.
Pharmaceutical research contractor Parexel International Corp. said on Tuesday that its fiscal second-quarter earnings jumped 65 percent as the company's backlog of contracts grew.
Vertex Pharmaceuticals Inc. swung to a loss in the fourth quarter as doctors turned away from the company's best-selling drug for treating hepatitis C.
Drug developer Isis Pharmaceuticals Inc. and partner Genzyme announced Tuesday that the U.S. Food and Drug Administration has approved their new drug application for Kynamro, clearing the way for Isis' first drug to reach market.
AbbVie delivered strong sales growth with its marketed pharmaceutical products in 2012. The proprietary pharmaceutical segment of Abbott, representing the majority of AbbVie's revenue, grew more than 8 percent globally on an operational basis.
The Facility of the Year Awards Judging Panel has named six Category Award Winners in the 2013 Facility of the Year Awards (FOYA) program. The winning projects for 2013 were selected from 27 well-qualified entries.
Metrics Inc. has named Dr. Thomas B. “Brad” Gold vice president of pharmaceutical development.
GlaxoSmithKline (GSK) and Biological E Limited (Biological E.), an Indian vaccines company, today announced an agreement to form a 50/50 joint venture (JV) for the early stage research and development of a six-in-one combination pediatric vaccine.
Shares of Repros Therapeutics Inc. plunged 40 percent Monday after the company said that results from a study of its testosterone drug Androxal will be delayed because it is removing some patients from the trial.
Eli Lilly and Co.'s fourth quarter earnings slipped 4 percent as generic competition continued to eat away at sales of its former best-seller, the antipsychotic Zyprexa, but the drugmaker cut expenses again and growth from other products helped it beat analyst expectations.
Nuvo Research Inc.announced today that it has entered into a settlement agreement with Apotex Inc. and Apotex Corp. (together Apotex) respecting patent infringement litigation brought by Nuvo and Nuvo's U.S. licensing partner, Mallinckrodt Inc. (Mallinckrodt), in response to Apotex's filing of an abbreviated new drug application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market a generic version of PENNSAID (diclofenac sodium topical solution) 1.5% w/w (PENNSAID).
Pfizer Inc. says its fourth-quarter profit more than quadrupled, despite competition from generic drugs hurting sales, because of a $4.8 billion gain from selling its nutrition business.
Amneal Pharmaceuticals, LLC today announced that it has entered into a license and distribution agreement with South Korea-based Hanmi Pharmaceutical Co., Ltd to acquire exclusive distribution rights to Hanmi's new drug application (NDA), currently under FDA review, for esomeprazole strontium delayed-release capsules.
Biogen Idec Inc. has announced full year and fourth quarter 2012 results.
The European Medicines Agency has been formally notified by Novartis Europharm Ltd of its decision to withdraw its application for a centralized marketing authorization for the medicine Ruvise.
A new strain of stomach bug sweeping the globe is taking over in the U.S., health officials say.
An attorney for creditors of a pharmacy blamed for a nationwide meningitis outbreak said Thursday that the firm paid out $70 million to company insiders over the last six years.
Orexo AB announced today that the company has entered into an agreement with AstraZeneca regarding OX-CLI, a preclinical program for a potential novel treatment of respiratory diseases.
AAIPharma Services Corp., a provider of pharmaceutical product development services, announced today that it has appointed James Fife as the company's senior director of parenteral operations for its manufacturing facility in Charleston, S.C.
International scientists who last year halted controversial research with the deadly bird flu say they are resuming their work as countries adopt new rules to ensure safety.